Discussion on suppressed information regarding IgG4 and COVID-19 implications.
-
Dr. McMillan emphasizes the importance of understanding autoimmunity in the context of the pandemic. • 0:03
-
A presentation on the potential consequences of falling vax antibodies was blocked from discussion. • 1:28
-
The concept of IgG4 and its implications are being suppressed by the scientific community. • 2:40
Concerns raised about potential implications of increased IgG4 levels post mRNA vaccination.
-
Increased IgG4 levels after mRNA vaccination may have significant implications. • 2:56
-
IgG4 levels can increase almost 4,000 times post mRNA vaccination. • 3:29
-
Vaccination with mRNA leads to a significant increase in IGG percentage. • 3:38
-
Severe COVID-19 is characterized by issues in the bloodstream, not just the lungs. • 5:13
-
Concerns about spike protein causing damage similar to the virus due to ACE2 binding. • 5:39
Discussion on potential autoimmune response triggered by circulating Spike protein and free A2 binding in severe covid-19 cases.
-
Circulating Spike protein binding to A2 may trigger autoimmune response in severe covid-19 cases. • 5:48
-
Elevated serum A2 levels linked to severe covid-19, especially in older individuals with comorbidities. • 6:39
-
Free floating A2 can potentially bind to Spike protein, leading to immune system targeting both. • 7:28
-
Autoantibodies to A2 observed in patients with severe covid-19, indicating autoimmune response. • 7:43
-
Theoretical possibility of free floating Spike protein binding to A2 and becoming a target for the immune system. • 8:08
-
IgG4 antibodies may play a role in dampening immune response to antigens, similar to bee venom tolerance. • 8:26
Discussion on implications of declining IgG4 levels in relation to severe COVID-19 and vaccination.
-
Elevated IgG4 levels may protect against cytokine storms and autoimmune responses. • 8:54
-
Decline in IgG4 levels could lead to severe COVID-19 post-vaccination. • 9:32
-
Challenges in managing individuals with elevated IgG4 levels and potential risks. • 10:12
-
Nuanced approach needed for addressing severe COVID-19 in boosted individuals. • 10:22
-
Lack of clarity on identifying individuals who may benefit from interventions. • 10:46
-
Political and scientific challenges in discussing and addressing these issues openly. • 11:04
-
Scientific community faces obstacles in raising difficult questions and addressing problems. • 11:13